ABSTRACT The roles of ergosterol in the regulation of membrane fluidity and structure, as well its role as a target for the activity of antifungals, have been known for decades. Two recent studies, however, demonstrated that ergosterol is an immunologically active lipid that induces pyroptosis and that virtually all steps of its biosynthetic process are potential drug targets. In combination, those two reports strongly indicate that the biological relevance of ergosterol is broader than the current literature suggests.
cell surface localization and/or total levels of ergosterol correlated with the ability of S. cerevisiae, C. albicans, and C. neoformans to trigger pyroptosis (5) . By using a filamentous strain of S. cerevisiae (⌺1278b) that induces inflammasome activation and a nonfilamentous strain (S288c) that does not, they identified a set of genes involved in ergosterol and membrane homeostasis as candidates to participate in the induction of pyroptosis-related macrophage lysis. Several genes required for macrophage lysis were also required for filamentation (5) . This suggests that fungal ergosterol may be the trigger for this mammalian cell process.
Such a relationship between ergosterol and pyroptosis has been implied by previous reports. The key transcriptional regulator of ergosterol biosynthesis, Upc2, was required for C. albicans-induced pyroptosis (9) , and functional deactivation of Upc2 function led to a reduced amount of cellular ergosterol (9, 13) . In the work from Koselny and colleagues, the first experimental evidence that ergosterol itself directly induces pyroptosis was its increased concentration in pyroptosis-inducing hyphal cells compared to yeast cells (5) . This was elegantly confirmed through the use of ergosterolcontaining and ergosterol-free liposomes in a macrophage pyroptosis model (5) . Only the ergosterol-containing liposomes were able to induce pyroptosis-mediated macrophage lysis. These results strongly suggest that there are mechanisms of ergosterol recognition by macrophages.
One concern about the findings summarized above is related to the fact that ergosterol is a typical plasma membrane component and therefore is not accessible to recognition by macrophage surface receptors. However, a number of C. albicans cell wall mannoproteins and related molecules have been demonstrated to bind and transport extracellular sterols (5), suggesting external distribution. In fact, ergosterol is a major lipid component of fungal extracellular vesicles (14) , which are the main vehicles of trans-cell wall transport in fungi (15) . The passage of ergosterol-containing vesicles through the cell wall implies that this sterol is a transitory cell wall component (16) , which might facilitate recognition by immune cells. In addition, ergosterolcontaining vesicles released extracellularly by C. albicans promote macrophage stimulation (17) . Therefore, a number of regular physiological processes support ergosterol export and consequent participation in immunological events. In this scenario, Koselny and colleagues (5) were the first to demonstrate that fungal ergosterol is immunologically active, which opens several avenues of investigation on how the host responds to sterols and fungal lipids in general.
ERGOSTEROL BIOSYNTHESIS PATHWAYS PROVIDE MULTIPLE TARGETS FOR ANTIFUNGAL DEVELOPMENT
The need for novel antifungals is unquestionable. Recent estimates report 1.6 million human deaths each year due to systemic mycoses (18) , and the currently available therapeutic options are unaffordable, toxic, or inefficient (19) . Ergosterol biosynthesis is still the most important cellular pathway targeted by antifungal compounds (2).
Ergosterol is synthesized in the endoplasmic reticulum through the sequential activity of 25 different enzymes (2). Upc2, the transcription factor required for pyroptosis in the C. albicans model, is directly related to the ergosterol biosynthesis pathway. This transcriptional regulator senses the intracellular levels of sterols, which results in the activation of genes required for sterol uptake and biosynthesis (13) . In the light of the findings reported by Koselny and colleagues (5) and the literature mentioned above, Upc2 is a central transcription factor regulating both fungal physiology and immunopathogenesis.
The currently available antifungal classes interfering with ergosterol synthesis affect the products of the ERG11 gene (14␣-demethylase; azoles), the ERG1 gene (squalene epoxidase; allylamines), and the ERG2 gene (sterol C-8 isomerase; morpholines). The potential of the 22 remaining genes required for ergosterol biosynthesis as antifungal targets remains to be explored. Most genes required for ergosterol synthesis are essential, which imposes difficulties with respect to the characterization of antifungal targets. In this scenario of great complexity, Bhattacharya and colleagues (6) overexpressed each of the 25 genes encoding the enzymes required for ergosterol biosynthesis in S. cerevisiae and characterized the phenotypic traits of each overexpressing strain in the presence of different stress agents. The impact of gene overexpression was 
remarkable. Strains with increased expression of HMG1, ERG9, ERG1, NCP1, ERG25, ERG27, ERG28, ERG6
, and ERG2, for instance, had decreased growth rates in rich medium and had their growth completely inhibited under conditions of iron deprivation. Calcium availability was also linked to ergosterol metabolism, as concluded from the lack of growth of 22 of the 25 strains in low calcium concentrations. Increased salt osmolarity also negatively affected the growth of 19 of the 25 strains, while cell wall perturbation with Congo red produced growth defects in 10 strains. These results efficiently illustrate the impact of ergosterol metabolism on fungal physiology and, consequently, reinforce the idea of the multiplicity of potential antifungal targets related to ergosterol biosynthesis. This view is supported by a global analysis of the findings reported by Bhattacharya and colleagues: overexpression of two genes (ERG2 and ERG6) had an effect on the activities of all stress agents, while overexpression of all 25 genes had an effect on the activity of at least one agent (6) .
Overexpression or viable deletion of ergosterol biosynthesis genes differently impacted the susceptibility of S. cerevisiae to fluconazole, fenpropimorph, lovastatin, nystatin, amphotericin B, or terbinafine (all affecting fungal ergosterol) (6) . In particular, exposure of the overexpressing strains to lovastatin, terbinafine, fluconazole, or fenpropimorph revealed that the previously known primary drug targets were not the only genes involved in the antifungal activity. Altogether, these results efficiently illustrate the view that the targets for antifungal development related to the ergosterol synthesis pathway are much more numerous than is understood in current practice.
PERSPECTIVES
The surface of fungal cells has been long recognized as a static molecular complex with exclusive structural functions. This classic view changed radically during recent decades after the demonstration that surface polysaccharides with well-described structural roles, including glucans, chitin, and mannan, were identified as key regulators of immunological activity (reviewed in reference 20). Fungal lipids, which were thought to be plasma membrane components exclusively, were demonstrated to be surface and extracellular components with key roles in fungal virulence (21) . These seminal observations and the report by Koselny and colleagues (5) clearly demonstrate that, rather than being a rigid structure with structural roles, the fungal surface is a highly dynamic molecular complex with great potential to stimulate the host's immune response (Fig.  1) . In addition, the multiplicity of composition and functions of the fungal cell surface agrees with the notion that a number of selective antifungal targets remain to be discovered, as demonstrated by Bhattacharya and coworkers (6) . The studies by Koselny and Bhattacharya and their colleagues (5, 6) open up new views on how the host interacts with fungal cells and how new possibilities of pharmacological interference in this process can be explored.
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